Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun;42(6):512-518.
doi: 10.1097/COC.0000000000000535.

Conditional Survival Analysis of Metastatic Colorectal Cancer Patients Living ≥24 Months: A Single Institutional Study

Affiliations
Clinical Trial

Conditional Survival Analysis of Metastatic Colorectal Cancer Patients Living ≥24 Months: A Single Institutional Study

Nadia D Ali et al. Am J Clin Oncol. 2019 Jun.

Abstract

Objectives: The survival of patients with metastatic colorectal cancer (CRC) has been increasing over recent decades due to improvements in chemotherapy and surgery. There is a need to refine prognostic information to more accurately predict survival as patients survive for any given length of time to assist multidisciplinary cancer management teams in treatment decisions.

Materials and methods: We performed a single center retrospective analysis of patients treated with metastatic CRC (unresectable and resectable) who survived >24 months between 2005 and 2015 (N=155). Patient tumor and treatment related variables were collected. Overall survival (OS) estimates conditional on surviving >24 months were compared with actuarial survival estimates of a cohort of patients (33,104 resected, 39,382 unresected) from the National Cancer Database (NCDB).

Results: With a median follow-up of 44.2 months, the median OS of resected patients (n=86) was not reached. The median OS of unresected patients was 75.9 months. The conditional survival probabilities of living 1, 2, or 3 years longer after 24 months of survival are 92%, 72%, and 52%, respectively, in unresectable patients and 98%, 92%, and 89% in patients who were resected. The corresponding NCDB 1, 2, and 3 year actuarial survival was 38%, 20%, and 11% for unresected patients and 68%, 46%, and 32% for resected.

Conclusions: These results indicate that CRC patients who survive 24 months with metastatic colorectal cancer have an excellent prognosis and surgery may be appropriate in a subset of patients initially deemed unresectable.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of the study population (A) and rationale of patients were unable to receive surgery with curative intent (B).
Figure 2.
Figure 2.
Initial sites of metastatic disease in 155 patients with metastatic colorectal cancer.
Figure 3.
Figure 3.
Overall survival of 155 patients with metastatic colorectal cancer in both resected and unresected settings.
Figure 4:
Figure 4:
A) Actuarial vs conditional probability of survival at 1, 2 and 3 years in resected metastatic colorectal cancer. B) Actuarial vs conditional probability of survival at 1, 2 and 3 years in unresected metastatic colorectal cancer.

References

    1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 67:7–30, 2017 - PubMed
    1. Guidelines N: NCCN Guidelines Colon Cancer. NCCN.org, NCCN, 22017
    1. Fakih MG: Metastatic Colorectal Cancer: Current State and Future Directions. Journal of Clinical Oncology 33:1809–1824, 2015 - PubMed
    1. Poston GJ, Figueras J, Giuliante F, et al.: Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 26:4828–33, 2008 - PubMed
    1. Hoff PM, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282–92, 2001 - PubMed

Publication types